|Oxford Pharm Gp
||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Oxford Pharm Gp Share Discussion Threads
Showing 801 to 825 of 825 messages
|Well, Ive been buying at these levels and averaging down from previous buys. I'm still convinced something will come good here and with many years of cash in the balance sheet, ongoing sales from the chew thingy (albeit not huge) it's not going to be placing or going out of business for a long time yet.|
|Cash, cash equivalents and short-term investments at 31 December 2016 of GBP21.9m (2015: GBP23.1m), affording flexibility to take selected products through to registration if deemed more likely to create greater shareholder value
So now below cash....|
|bought back in today. Just a few.....never lost on these and nearly halved now since that rns.|
|Lucky mr risk one shroud dude|
|You tell them Barnes
Mr Risk1 made 350K on this, he dumped all in the spike|
|Why are you sorry
Nothing much has changed
As long as you don't sell you have lost nowt!!|
|thanks from me too timbo
kept your research and warnings in mind when
I bought the chart and then sold in Feb.
Sorry for those still holding today.|
|Timbo...right again!! Many on here took their profits from the 1.7 levels and did not hang around....usually because of yr warnings that this was hopeless. This time the price may tank to one pence....|
|Thank you Timbo. I'll read them with great interest.|
All they have is a simple mix of ibuprofen and an antacid (think of it as Nurofen plus Malox)
If you give them together in the right ratio you reduce the GI effects, but reduce the rate of ibuprofen absorbed (slow onset) and the amount absorbed (ineffective dose)
If you change the ratio so there is only a slight reduction in rate of absorption and a slight decrease in the amount absorbed you lose any GI benefits
I have posted on this numerous times over the years, here are some links:
|"Alternatively, the FDA has suggested the Company could pursue a claim of reduced GI symptoms only, without requiring such a clinical outcomes study"
I wonder if it would not be sufficient to claim 'reduced GI symptoms'. It's known Ibuprofen causes/increases GI problems and that's a big problem. If I were a doctor, just to be on the safe side and better for the patient, I would prescripe the one that has proven to reduce GI symptoms.|
|Have to say Timbo, you called this right, yet to my chagrin I am still a holder.|
|Why is the technology totally flawed in your opinion?|
|A very predictable outcome from the FDA pre-IND meeting Rx use.
Why does anyone invests in this company?
It is okay saying the cash is equal to the market cap if they are likely to do some thing productive with the cash other than waste it on pipe-dreams, but it is quite evident they are not. The technology (if you can call it that) if totally flawed.
I now look forward to the fairly predictable feedback from the pre-IND OTC proposal.
As an aside, I see that shares are being offered in the IPO (reverse takeover) of another one of Nigel Theobald's Pipedreams: N4 pharma. That's another one to put into the barge-pole bin.
|Mmmm.... a bit of a false dawn, today - the rise appears to have been soon sold into, even though still standing higher than previouly.
|OXP has moved up quite a % bit in the last week. Looks quite strongish to me, with a 100k lot taken at 3.03p just this minute.
|There were some large trade at 3p and above. I feel that there is no smoke without fire and they will be pulled back up. I unfortunately took a profit at 2.18 and missed on the rise. Anyone any have any sensible entry point views?|
|Dips being bought, looking for another run to 3.5p pre news. Good news should see this back to 10p placing price.
It can happen. Just tuck them away and trade something else IMO.|
|PU, many thanks for the snippet on surface transforms. I will respond in more detail later, I'm currently on a plane (to Vegas) waiting to take off, hence the brevity.|
Re SCE - I think you are a holder - Had a chat with DB recently and also looked at web cast - Time lines extended but will continue to hold risk/reward (imo) still tilted in favour of reward. (If of any use to you) Usual cautions apply|
No, I remain very sceptical|
|I'm not sure they've given up on the GI part.
"This study is to help development of a new version of Ibuprofen, called Ibuprofen-LDH. Ibuprofen-LDH will be used as a treatment for muscular pains, headache, fever etc. This new version of ibuprofen is expected to produce fewer stomach/intestine related side effects when compared to many existing marketed formulations of Ibuprofen."
I sure hope they haven't as I see the GI part as the most interesting.|
Can you translate please into consumer speak and also have you changed your mind about the technology (your post 730 above) so as to make this worth looking at again.|
|Good to see that they have given up trying to obtain GI safe claims for an OTC formula, as this was always a non-starter as far as I was concerned. I doubt if they will get improved taste masking with faster acting, but they should be able to achieve taste masking without the speed claims.|
|Very good news. Having trust in an increasing share price|